

Poster presentation schedule

Tuesday, 21 November 2023

09:30 – 10:25

Clinical Pharmacology	
P500	Computational video analysis for treatment and deprescribing evaluation in ageing mice Dr Kenji Fujita, Kolling Institute, The University of Sydney
P502	Outcomes of considering goals of care in medication review: a systematic review Dr Nashwa Masnoon, Kolling Institute, The University of Sydney and Northern Sydney Local Health District
P504	Developing a tool to evaluate organisational culture and psychotropics use in RACF Boyi Chen, The University of Sydney
P506	Identifying priorities for medication management resources for people with dementia and carers Dr Mouna Sawan, The University of Sydney
P508	Cannabidiol in sport and exercise Prof Michael Kennedy, Clinical Pharmacology, St Vincent's Hospital Sydney
P510	An efficient HILIC-MS/MS method for monitoring metformin in human plasma A/Prof Mei Zhang, Department of Medicine, The University of Otago - Christchurch
P512	Ethnic differences in the safety and efficacy of tyrosine kinase inhibitors Nicki Kyriacou, The University of Sydney
P514	Thioguanine efficacy, safety and TDM in IBD patients in New Zealand Prof Murray Barclay, Christchurch Hospital
P516	The effect of compulsory indications in electronic hospital prescriptions on prescriber behaviour Lorna Pairman, The University of Otago

Drug Discovery	
P518	Influence of tumour microenvironment on the activity of breast cancer therapeutic agents Xiaodan Zhang, The University of Melbourne
P520	Calcium signalling and the breast cancer microenvironment Dr Farzaneh Forouz, The University of Queensland
P522	Inducing conformational bias via fluorination to enhance selectivity and potency of imipramine Ishika Jaitly, UNSW Sydney
P524	TRPA1 expression in joints and DRGs of monoiodoacetate-induced rat knee OA pain Scarlett Desclaux, Mahidol University
P526	Exploring calcium signalling remodelling during adaptive cancer drug tolerance Melanie Robitaille, The University of Queensland
P528	8-Shogaol suppresses rheumatoid arthritis by direct inhibition of TAK1 Yong Joon Lee, Yonsei University
P530	Combining LC-MS/MS with bioinformatic approaches for understanding bioactivities of propolis Eun Heo, Yonsei University
P532	Hydroxychavicol inhibits expression and activity of MMP-9 induced by RANKL in osteoclasts Wisuttaporn Inthanop, Faculty of Medicine Ramathibodi Hospital, Mahidol University
P534	Oleanolic acid and syringic acid induce fat browning through UCP1 activation A/Prof Chang Ik Choi, Dongguk University
P536	Exploring molecular determinants underpinning high potency of MIPS3215 at adenosine A2B receptor Cam Sinh Lu, Monash University
P538	Exploring A2B receptor regulated human cardiac fibroblast phosphoproteome for fibrosis target discovery Joel Coffie, Monash University
P540	A novel single-cell fluorescence-microscopy based analysis for detection of biomarkers of cellular-senescence Vijayraghavan Seshadri, The University of Tasmania
P565	Exploring Spexin-1 and Predicted Spliceforms: Insights into GPR161 and GAL2R Signalling Kinjal Patel, UNSW Sydney

Tuesday, 21 November 2023

09:30 – 10:25

Respiratory and Inflammation	
P542	Re-examining IRAK3 - an essential homeostatic checkpoint immune protein Dr Helen Irving, La Trobe University
P544	Ebselen is unable to restore established cigarette smoke-induced neurocognitive dysfunction Alina Akhtar, RMIT University
P546	Human osteoclast differentiation after induction by mRNA of NFATc1 Dr Sirada Srihirun, Mahidol University
P548	Pulmonary and vascular consequences of influenza A virus infection in atherosclerotic mice Madison Coward-Smith, RMIT University

Innovation and Industry	
P550	Development of a Precision Medicine Competency Framework for the Therapeutics Industry Dr Orin Chisholm, The University of Sydney
P552	New methods for designing patient-centred clinical trials for epilepsy and cannabidiol drugs Linda Truong, The University of Newcastle
P554	Nonclinical and Manufacturing Considerations for Novel Live Biotherapeutic Products Dr Sharleen Menezes, Novotech
P556	Nonclinical and CMC Considerations for the Development of siRNA Therapeutics Sweta Kumar, Novotech

Toxicology	
P558	Stress-driven suppression of the Hippo pathway accelerates liver injury Ja Hyun Koo, Seoul National University
P560	Computational models of retinoic acid receptor antagonists acting as endocrine disrupting chemicals Raymond Lui, The University of Sydney
P561	MEHP-induced apoptosis, autophagy, and endoplasmic reticulum stress in human neurons and astrocytes Ratchanon Sukprasert, Faculty of Allied Health Sciences, Burapha University
P563	Fluoroquinolone ameliorates cadmium-induced pro-inflammatory cytokine production in human astrocytes Suttinee Phuagkhaopong, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University

Clinical Pharmacology

P501	Sustainability of in-hospital deprescribing: a scoping review with a systematic approach Angela John, The University of Sydney
P503	Co-designing medication management resources for people with dementia and carers during hospitalisation Alexander Clough, The University of Sydney
P505	Patient's experience of a psychiatric, alcohol and non-prescription drug assessment (PANDA) unit Hannah Paul, UNSW Sydney
P507	Effects of alcohol on blood glucose in patients with type-1 diabetes mellitus A/Prof Hesham Al-Sallami, School of Pharmacy, The University of Otago
P509	Routine Therapeutic Drug Monitoring of Rivaroxaban: Experience at a Tertiary Center Dr Paul Chin, The University of Otago
P511	Equity and Quality Use of Medicines in people presenting to PANDA Unit Dr Jana Stojanova, St Vincent's Hospital Sydney
P513	Four-year review of NZ laboratory infliximab/adalimumab concentrations indicates potential for improved dosing Prof Murray Barclay, Christchurch Hospital
P515	The Utility of Education Materials and Decision Aids to Guide Medication Management Joseph Boutros, The University of Sydney

Drug Discovery

P517	CK1δ inhibitor PF670462 has anti-tumorigenic activity in the TNBC cell line, MDA-MB-231 Jana Zielinski, The University of Melbourne
P519	Modulation of T- type Calcium Channel 3.1 by Cannabidiol and enantiomer +CBD Dr Chris Bladen, Macquarie University
P521	Targeting casein kinase 1 delta/epsilon in hepatocellular carcinoma Gretel Happell, The University of Melbourne
P523	Developing nanobodies as subtype-selective α1A adrenergic receptor tools Saund Yadanar, Monash University
P525	Developing a human cell model to study calcium signalling during coronavirus infection Shao Ming Chan, The University of Queensland
P527	Assessing gene expression of pannexin isoforms in breast cancer cell lines Monami Ghosal, The University of Queensland
P529	Gene expression of calcium signalling modulators in SARS-CoV-2 infection Mia Akison, The University of Queensland
P531	Selective killing of mTORC1-hyperactive cancer cells through targeting the RUVBL1/2-TTT pathway Ji Su Lee, Yonsei University
P533	Hydroxychavicol inhibits RANKL-induced expression of osteoclast-specific genes Pitchanun Kongphanich, Mahidol University
P535	The effect of C.racemosa extract on anti-wrinkle and anti-melanogenesis in skin cells Ratchanon Sukprasert, Faculty of Allied Health Sciences, Burapha University
P537	Developing an optogenetic system to shine a light on intracellular GPCR signalling Chantel Mastos, Monash University
P539	Characterisation of the pro-atherosclerotic orphan G protein-coupled receptor, GPR146 Brendan Wilkins, UNSW Sydney

Respiratory and Inflammation

P541	A soft microenvironment uncouples TGF-beta signaling from fibrogenesis in human pulmonary fibroblasts Avanka Gunatilaka, The University of Melbourne
P543	Bombesin Receptor Subtype 3 as a potential target for lung adenocarcinoma Mariah Stavrou, UNSW Sydney
P545	Casein kinase 1 delta/epsilon inhibition: a promising solution to unaddressed airway remodelling Nguyen Thi Hanh Tran, The University of Melbourne
P547	Involuntary exercise did not improve cigarette smoke-induced anxiety-like behaviour in male mice. Rana Alateeq, RMIT University
P549	A 3D mesothelioma co-culture model to improve translational potential of immunotherapy treatments Aimee Stenekes, University of Technology Sydney

Innovation and Industry	
P551	Bone regeneration potential of 3D printed hydroxyapatite in a rat model Ticomporn Luangwattanawilai, Mahidol University
P553	What is a Non-Significant Risk Device Clinical Study? Melissa Dworak, Novotech
P555	Automated In-Vitro Population Bioequivalence for Inhaled Products Using Phoenix® WinNonlin® Dr Chandramouli Radhakrishnan, Certara

Toxicology	
P557	Oxyresveratrol and resveratrol attenuate cadmium-induced cytokine release in human astrocytes A/Prof Pornpun Vivithanaporn, Mahidol University, Faculty Of Medicine Ramathibodi Hospital - Bangkok
P559	Impact of target expression on target safety assessment of ADCs Phumzile Sikakana, Apconix
P562	Application of Bayse Theorem to augment machine learning predictions of Ames mutagenicity Daniella James-New, The University of Sydney
P564	Acute toxicity of Thai PM 2.5 in zebrafish embryos Pinnakarn Techapichetvanich, Mahidol University

Poster presentation schedule

Wednesday, 22 November 2023

09:30 – 10:25

Cardiovascular	
P600	The Role of Interleukin-18 Receptor Accessory Protein in Hypertensive Chronic Kidney Disease Buddhila Wickramasinghe, La Trobe University
P602	Comparing the anti-fibrotic potential of exosome-based therapies in human myofibroblasts in vitro Jennie Charoenphannathon, Monash University
P604	RAGE expression and function in myometrial arteries during gestational diabetes. Dr Timothy Murphy, UNSW Sydney
P606	Neurogenic inflammation exacerbates urinary tract infection in mice Harman Sharma, Flinders University
P608	Impact of exercise on the heart in a mouse model of obesity Nimna Perera, Monash Institute of Pharmaceutical Sciences
P610	Sex matters– impact of HFD and low-dose SGLT2i on rodent cardiometabolic phenotype Abhipree Sharma, Monash University
P612	Targeting the AT4 receptor/IRAP reverses type 2 diabetes-induced cardiovascular dysfunction and remodelling Cameron Hollands, Monash University

Drug Disposition and Response	
P614	Critical evaluation of topical zinc pyrithione anti-fungal therapeutics Sean Mangion, The University of South Australia
P616	Describing plasmapheresis (PLEX): PLEX, the patient and impact on therapy Susie Welch, St Vincent's Hospital Sydney

Education	
P620	Nutrition counselling in Pharmacy Practice in Australia Samar Elsayed, School of Pharmacy, The University of Sydney
P622	Altered preference from online to face-to-face workshops does not influence academic outcomes Dr Elvan Djouma, La Trobe University
P624	Scaffolding resilience skill development across an undergraduate Pharmacy curriculum Dr Betty Exintaris, Monash University
P626	Accessing lecture recordings as a supplement or a substitute to lecture attendance Dr Sheila Doggrell, Griffith University

Neuropharmacology	
P628	Novel treatments targeting neurodegeneration and inflammation attenuate repetitive mild traumatic brain injury Dr Andrew Fenning, CQ University
P630	Modulation of neuronal ion channels by metabolites of cannabidiol Prof Mark Connor, Macquarie University
P632	Epilepsy-causing proline paralog variant in GABAA-receptor display distinct functional properties between subunits Sze Hon Kan, Brain and Mind Centre, The University of Sydney
P634	A novel system for determining CB1 activity by employing the operational model Humayra Zaman, Macquarie University
P636	Modulation by CBD metabolite decreases THC signalling via CB1 in vitro Zoe Adam, Macquarie University

Wednesday, 22 November 2023

09:30 – 10:25

Pharmacogenomics

P638	Personalising selection of antifungals: can we predict lack of response to voriconazole? Eman Wehbe, The University of Sydney
------	---

Pharmacoepidemiology

P641	Poisonings in older adults with dementia: a systematic scoping review and meta-analysis Ilsa Wojt, The University of Sydney
P643	Prevalence of and risk factors for drug-related readmissions in older adults Narisha Prasad, The University of Sydney

Urogenital and Gastrointestinal

P645	Consistencies between carbachol-induced contractions to clinical antimuscarinics in differently aged porcine bladders Vineesha Veer, Bond University
P647	Contractile response of the urothelium/lamina propria depressed by acute hypoxia in vitro Elouise Tye, Bond University
P649	The Functional Role of Phosphodiesterase Isoenzymes in the Isolated Porcine Urethra Eriq Burovski, Bond University

Cardiovascular	
P601	Is there now evidence for rethinking statin dose? Prof Simon Dimmitt, Universities of Western Australia And Newcastle
P603	Interleukin-1 beta via Smad2 transcription factor promotes glycosaminoglycan chain synthesising gene expression Hirushi Kumarapperuma, The University of Queensland
P605	Natriuretic peptide receptors in vascular smooth muscle cells in tissue versus culture Christine Rager, Monash University
P607	Inhibition of the AT4R/IRAP to reduce renal fibrosis in chronic kidney disease Sharenja Chelvaretnam, Monash University
P611	Lipoxin A4 improves cardiac remodelling and function in diabetes-associated cardiac dysfunction Ting Fu, Monash University

Drug Disposition and Response	
P613	Protein and RNA characterisation of rapidly maturing CLEFF4 and parent Caco2 cells Dr Andrew Crowe, Curtin University
P615	Visualising the topical delivery of retinoids Sean Mangion, The University of South Australia
P617	Antibiotic combinations against Pseudomonas aeruginosa strains with different resistance mechanisms Alice Terrill, Monash University

Education	
P619	Perceptions of third-year undergraduate pharmacology students on teamwork Arani Dasanayake, Monash University
P621	Using clinical case studies to build professional skills: A case study Dr Suong N T Ngo, The University of Adelaide
P623	Use of a baseline teamwork assessment tool in undergraduate pharmacology A/Prof Lynette Fernandes, The University of Western Australia
P625	Streamlining Nursing Home Discharges from the Acute Hospital Setting Dr Betty Exintaris, Monash University
P627	Evaluating pharmacogenomics education on medical, pharmacy and nursing student knowledge and confidence Ruby Soueid, The University of Sydney

Neuropharmacology	
P629	Osteoarthritis, opioids, & polypharmacy: deprescribing outcomes in middle-aged male & female mice Charlie Gregson, Kolling Institute
P631	Structural Insights into Positive Allosteric Modulation at the M4 mAChR Michaela Kaoullas, Monash Institute of Pharmaceutical Sciences
P633	A new system to determine Cannabinoid receptor-2 (CB2) ligand efficacy Tahira Foyzun, Macquarie University
P635	Endocannabinoid related derivatives of polyunsaturated fatty acids (PUFAs) activate TRPV1 ion channel Atnaf Abate, Macquarie University

Pharmacoepidemiology	
P637	Real-world evidence of antipsychotic utilization in Australia (2000–2021) using two datasets Ramya Padmavathy Radha Krishnan, The University of Sydney
P639	Psychotropic use in older people with and without dementia in Australia Edward Lau, The University of Sydney
P642	The availability of mobile applications to facilitate deprescribing: A scoping review Lina Okati, The University of Sydney
P644	Six-country comparison of antimicrobial consumption in Latin American hospitals Maria Jose Alfonso Arvez, Monash University

Urogenital and Gastrointestinal	
P646	5-HT₃ receptors moonlight in mitochondria above their steady job at plasma membrane Santosh RamaBhadra Rao Tata, La Trobe University
P648	Lactobacillus salivarius HHunMin-U enhances the innate immune response against Norovirus infection Jay-young Jo, Yonsei University
P650	Comparison of diabetes-induced bladder dysfunction in vitro and in vivo Aidan Mckee, Bond University